Antibody-drug conjugates: beyond current approvals and potential future strategies

The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic cell surface antigens with the additional cell kill from high...

Full description

Bibliographic Details
Main Authors: Siddharth Menon, Sagun Parakh, Andrew M. Scott, Hui K. Gan
Format: Article
Language:English
Published: Open Exploration Publishing Inc. 2022-04-01
Series:Exploration of Targeted Anti-tumor Therapy
Subjects:
Online Access:https://www.explorationpub.com/Journals/etat/Article/100282